MedTrace Logo

Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients

NCT04389645 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2020-05-15

No results posted yet for this study

Summary

The proposed project will pilot incorporation of rapid serial measurements of IP-10 into a CDS tool for moderate and severe COVID-19 patients.

The tool was applied to all comers with confirmed COVID-19 diagnosis at a secondary medical center in Israel.

Conditions

Interventions

DIAGNOSTIC_TEST

IP-10 in CDS protocol

Dynamic IP-10 measurements in hospitalized COVID-19 positive patients

Sponsors & Collaborators

  • MeMed Diagnostics Ltd.

    lead INDUSTRY

Principal Investigators

  • Shaul Lev, MD · Rabin Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-07
Primary Completion
2020-05-12
Completion
2020-05-12

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04389645 on ClinicalTrials.gov